ATE480240T1 - Zusammensetzung enthaltend latanoprost und behandlungsmethode von erhöhtem augeninnendruck und glaukom - Google Patents
Zusammensetzung enthaltend latanoprost und behandlungsmethode von erhöhtem augeninnendruck und glaukomInfo
- Publication number
- ATE480240T1 ATE480240T1 AT03758746T AT03758746T ATE480240T1 AT E480240 T1 ATE480240 T1 AT E480240T1 AT 03758746 T AT03758746 T AT 03758746T AT 03758746 T AT03758746 T AT 03758746T AT E480240 T1 ATE480240 T1 AT E480240T1
- Authority
- AT
- Austria
- Prior art keywords
- glaucoma
- treatment
- composition containing
- eye pressure
- increased eye
- Prior art date
Links
- 208000010412 Glaucoma Diseases 0.000 title abstract 2
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 title abstract 2
- 229960001160 latanoprost Drugs 0.000 title abstract 2
- 208000001344 Macular Edema Diseases 0.000 abstract 2
- 206010025415 Macular oedema Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 201000010230 macular retinal edema Diseases 0.000 abstract 2
- 206010030043 Ocular hypertension Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229960000686 benzalkonium chloride Drugs 0.000 abstract 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Solid Thermionic Cathode (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42077602P | 2002-10-24 | 2002-10-24 | |
| US42104402P | 2002-10-25 | 2002-10-25 | |
| US10/429,677 US7074827B2 (en) | 2002-10-24 | 2003-05-06 | Method for treating ocular hypertension and glaucoma |
| PCT/JP2003/013452 WO2004037267A1 (en) | 2002-10-24 | 2003-10-22 | Method and composition containing latanoprost for treating ocular hypertension and glaucoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE480240T1 true ATE480240T1 (de) | 2010-09-15 |
Family
ID=32110845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03758746T ATE480240T1 (de) | 2002-10-24 | 2003-10-22 | Zusammensetzung enthaltend latanoprost und behandlungsmethode von erhöhtem augeninnendruck und glaukom |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7074827B2 (de) |
| EP (2) | EP1553953B1 (de) |
| JP (2) | JP2006503913A (de) |
| AT (1) | ATE480240T1 (de) |
| AU (1) | AU2003274734A1 (de) |
| CA (1) | CA2502437C (de) |
| DE (1) | DE60334134D1 (de) |
| DK (1) | DK1553953T3 (de) |
| WO (1) | WO2004037267A1 (de) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1667705A1 (de) * | 2003-10-03 | 2006-06-14 | Allergan, Inc. | Zusammensetzungen und verfahren mit prostaglandin-verwandten verbindungen und peptiden der trefoil-faktor-familie zur behandlung von glaukom mit verringerter hyperämie |
| EP1655021B1 (de) * | 2004-11-09 | 2008-10-29 | Novagali Pharma SA | Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential |
| GB0501192D0 (en) * | 2005-01-20 | 2005-03-02 | Resolution Chemicals Ltd | Stable prostaglandin-containing compositions |
| DE102005035986B4 (de) * | 2005-07-28 | 2009-10-15 | Bausch & Lomb Incorporated | Steriles tropfbares mehrphasiges emulgatorfreies ophthalmisches Präparat |
| PL1937212T3 (pl) * | 2005-10-10 | 2011-02-28 | Santen Sas | Emulsje oftalmiczne zawierające prostaglandyny |
| WO2007111806A2 (en) | 2006-03-23 | 2007-10-04 | Massachusetts Eye And Ear Infirmary | Cyclopentane heptanoic acid compounds for reducing body fat |
| TWI394564B (zh) * | 2006-09-21 | 2013-05-01 | Alcon Res Ltd | 自行保存型水性藥學組成物 |
| MX2009003042A (es) * | 2006-09-28 | 2009-04-02 | Alcon Res Ltd | Composiciones farmaceuticas acuosas auto-preservadas. |
| FR2912207B1 (fr) * | 2007-02-01 | 2012-10-26 | Air Liquide | Procede et appareil de production de monoxyde de carbone par distillation cryogenique |
| JPWO2008096804A1 (ja) * | 2007-02-07 | 2010-05-27 | テイカ製薬株式会社 | ラタノプロスト含有点眼剤 |
| JP2008247828A (ja) * | 2007-03-30 | 2008-10-16 | Wakamoto Pharmaceut Co Ltd | ラタノプロストを含有する水性医薬組成物。 |
| FR2918891B1 (fr) * | 2007-07-20 | 2009-09-25 | Thea Sa Lab | Solution ophtalmique a base de prostaglandines sans conservateur |
| JP2009040727A (ja) * | 2007-08-09 | 2009-02-26 | Towa Yakuhin Kk | ラタノプロストを有効成分とする安定な点眼液剤 |
| EP2193795B1 (de) * | 2007-08-29 | 2014-10-01 | Wakamoto Pharmaceutical Co., Ltd. | Latanoprosthaltige wässrige pharmazeutische zusammensetzung |
| MX2007011165A (es) * | 2007-09-12 | 2009-03-11 | Arturo Jimenez Bayardo | Composición farmacéutica estable de timolol, dorzolamida y brimonidina. |
| SI2254549T2 (sl) * | 2008-03-17 | 2019-08-30 | Alcon Research, Ltd. | Vodni farmacevtski sestavki, ki vsebujejo komplekse borata/poliola |
| TWI544927B (zh) | 2008-03-17 | 2016-08-11 | 愛爾康研究有限公司 | 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物 |
| EP2127638A1 (de) | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Verfahren und Zusammensetzung zur Behandlung von Augenhochdruck und Glaukom |
| EP2228058A1 (de) | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Anionische Öl-in-Wasser-Emulsion mit Prostaglandinen und Verwendungen dafür |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US20100298335A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and Methods for Ameliorating or Reducing Presbyopia |
| US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| JP2010275259A (ja) * | 2009-05-29 | 2010-12-09 | Toa Yakuhin Kk | 均一、かつ安定なラタノプロスト点眼液剤組成物 |
| TWI489997B (zh) * | 2009-06-19 | 2015-07-01 | Alcon Res Ltd | 含有硼酸－多元醇錯合物之水性藥學組成物 |
| EP2269575A1 (de) | 2009-06-30 | 2011-01-05 | Santen Pharmaceutical Co., Ltd | Verfahren zur Verbesserung der Bioverfügbarkeit von Latanoprost |
| EP2389939A1 (de) | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Verwendung von Prostaglandinen F2alpha und Analoga zur Heilung von Horn- und Bindehautläsionen |
| BR112012023421B1 (pt) * | 2010-03-17 | 2021-09-14 | Novaliq Gmbh | Composição farmacêutica para tratamento de aumento de pressão intraocular |
| FR2961694B1 (fr) | 2010-06-29 | 2013-01-25 | Thea Lab | Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur |
| US20130245124A1 (en) * | 2010-07-29 | 2013-09-19 | Allergan, Inc. | Preservative free bimatoprost solutions |
| US9061034B2 (en) | 2010-07-29 | 2015-06-23 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
| JP6014033B2 (ja) | 2010-07-29 | 2016-10-25 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 防腐剤無添加ビマトプロストおよびチモロール溶液 |
| EP2452669A1 (de) | 2010-10-29 | 2012-05-16 | Omnivision GmbH | Ophthalmische Zusammensetzung |
| EP2462921A1 (de) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Flüssige pharmazeutische Zusammensetzungen zur Behandlung einer Erkrankung der Hinterseite des Auges |
| US9089579B2 (en) | 2011-01-19 | 2015-07-28 | Topokine Therapeutics, Inc. | Methods and compositions for treating metabolic syndrome |
| US8426471B1 (en) | 2011-12-19 | 2013-04-23 | Topokine Therapeutics, Inc. | Methods and compositions for reducing body fat and adipocytes |
| CN107970506B (zh) | 2012-04-10 | 2020-06-16 | 艾诺维亚股份有限公司 | 具有可控制的微滴电荷的定向微滴流在制备药物中的用途 |
| AU2013249108A1 (en) | 2012-04-20 | 2014-12-04 | Eyenovia, Inc. | Spray ejector device and methods of use |
| CA2873276A1 (en) | 2012-05-14 | 2013-11-21 | Eyenovia, Inc. | Laminar flow droplet generator device and methods of use |
| EP2849949A4 (de) | 2012-05-15 | 2017-07-26 | Eyenovia, Inc. | Auswerfervorrichtungen, verfahren, treiber und schaltungen dafür |
| EP4342537A3 (de) | 2012-09-12 | 2024-07-03 | Novaliq GmbH | Semifluorierte alkanzusammensetzungen |
| EP3100722B1 (de) | 2012-09-12 | 2024-03-20 | Novaliq GmbH | Semifluorierte alkane zur solubilisierung von meibum |
| EP2922542A4 (de) | 2012-11-21 | 2016-10-05 | Topokine Therapeutics Inc | Verfahren und zusammensetzungen zur lokalen körperfettvermehrung |
| WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
| NO2753788T3 (de) | 2013-05-10 | 2018-06-16 | ||
| WO2014186504A1 (en) | 2013-05-15 | 2014-11-20 | Topokine Therapeutics, Inc. | Methods and compositions for topical delivery of prostaglandins to subcutaneous fat |
| JPWO2015029923A1 (ja) * | 2013-08-26 | 2017-03-02 | ロート製薬株式会社 | 眼科用製剤 |
| GR1008483B (el) * | 2013-12-23 | 2015-05-12 | Rafarm Α.Ε.Β.Ε., | Οφθαλμικη φαρμακευτικη συνθεση και μεθοδος για την παρασκευη αυτης |
| US10188661B2 (en) | 2014-06-27 | 2019-01-29 | Topokine Therapeutics, Inc. | Topical dosage regimen |
| JP6604328B2 (ja) | 2014-08-05 | 2019-11-13 | ソニー株式会社 | 直流電力送電装置、直流電力受電装置及び直流電力送電システム |
| DE202016008738U1 (de) | 2015-09-30 | 2019-04-09 | Novaliq Gmbh | Semifluorierte Verbindungen und ihre Zusammensetzungen |
| EP3356313B1 (de) | 2015-09-30 | 2020-05-06 | Novaliq GmbH | 2-perfluorhexyl-octan zur ophthalmologischen verabreichung |
| GR1009040B (el) * | 2016-04-19 | 2017-05-19 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου |
| JP2019520357A (ja) | 2016-06-23 | 2019-07-18 | ノバリック ゲーエムベーハー | 局所投与方法 |
| PL3515420T3 (pl) | 2016-09-22 | 2024-04-08 | Novaliq Gmbh | Kompozycje farmaceutyczne do zastosowania w terapii zapalenia brzegów powiek |
| CA3036306C (en) | 2016-09-23 | 2024-05-14 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| EP3399962B1 (de) | 2016-12-23 | 2020-06-10 | Novaliq GmbH | Ophthalmische zusammensetzung zur behandlung von trockenem auge |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| MX2020003534A (es) | 2017-09-27 | 2020-07-29 | Novaliq Gmbh | Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares. |
| CN119909046A (zh) | 2017-10-04 | 2025-05-02 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
| US11576893B2 (en) | 2018-03-02 | 2023-02-14 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
| CN112153970A (zh) | 2018-04-27 | 2020-12-29 | 诺瓦利克有限责任公司 | 用于治疗青光眼的包含他氟前列素的眼用组合物 |
| CN112823020A (zh) | 2018-10-12 | 2021-05-18 | 诺瓦利克有限责任公司 | 用于治疗干眼病的眼用组合物 |
| EP3923907B1 (de) | 2019-02-13 | 2024-09-25 | Novaliq GmbH | Zusammensetzungen und verfahren zur behandlung von okularer neovaskularisation |
| US12539302B2 (en) | 2019-08-07 | 2026-02-03 | Aneira Pharma, Inc. | Methods and compositions for the treatment of hair loss |
| PL3886799T3 (pl) | 2019-08-07 | 2024-03-18 | Aneira Pharma, Inc. | Kompozycje do leczenia utraty włosów |
| CA3149046A1 (en) | 2019-09-06 | 2021-03-11 | Jorg Haisser | Ophthalmic composition for the treatment of uveitis |
| JP2022120120A (ja) * | 2022-06-13 | 2022-08-17 | 東亜薬品株式会社 | 眼科用水性組成物及びプロスタグランジンＦ２α誘導体の含量の低下を抑制する方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5296504A (en) * | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| EP1225168B8 (de) * | 1988-09-06 | 2015-03-18 | Pfizer Health AB | Prostaglandin-F-2-alpha Derivat zur Behandlung von Glaukom und Augenhochdruck |
| AU665287B2 (en) | 1992-12-21 | 1995-12-21 | Alcon Laboratories, Inc. | Prostaglandin combinations in glaucoma therapy |
| WO1997023225A1 (en) | 1995-12-22 | 1997-07-03 | Alcon Laboratories, Inc. | Combinations of dp and fp type prostaglandins for lowering iop |
| JPH10259179A (ja) * | 1996-09-19 | 1998-09-29 | Santen Pharmaceut Co Ltd | 多置換アリールオキシ基を有するプロスタグランジン類およびその用途 |
| AR002194A1 (es) | 1997-03-17 | 1998-01-07 | Sanchez Reynaldo Alemany | Instrumento computarizado para el analisis del movimiento. |
| US6646001B2 (en) | 1997-12-19 | 2003-11-11 | Alcon Manufacturing, Ltd. | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension |
| JP4000505B2 (ja) * | 1999-12-01 | 2007-10-31 | 第一三共株式会社 | 緑内障を治療するための併用剤 |
| SE0002211D0 (sv) | 2000-06-13 | 2000-06-13 | Synphora Ab | Methods and compositions for prevention of myopia |
| US20020035148A1 (en) * | 2000-07-20 | 2002-03-21 | Ryuji Ueno | Treatment of ocular hypertension |
| US20040097592A1 (en) | 2000-09-13 | 2004-05-20 | Kenji Morishima | Eye drops |
| JP3876355B2 (ja) * | 2000-09-13 | 2007-01-31 | 参天製薬株式会社 | 点眼液 |
| US20030018079A1 (en) * | 2000-11-13 | 2003-01-23 | Richardson Helene | Treatment |
| US8549114B2 (en) * | 2002-06-12 | 2013-10-01 | Bladelogic, Inc. | Method and system for model-based heterogeneous server configuration management |
| DK1532981T3 (da) | 2002-08-23 | 2008-01-28 | Santen Pharmaceutical Co Ltd | Stabile öjendråber, der indeholder latanoprost som den aktive bestanddel |
| US8143312B2 (en) | 2002-09-09 | 2012-03-27 | Santen Pharmaceutical Co., Ltd. | Transparent eye drops containing latanoprost |
-
2003
- 2003-05-06 US US10/429,677 patent/US7074827B2/en not_active Expired - Fee Related
- 2003-10-22 DK DK03758746.6T patent/DK1553953T3/da active
- 2003-10-22 CA CA2502437A patent/CA2502437C/en not_active Expired - Fee Related
- 2003-10-22 JP JP2005501572A patent/JP2006503913A/ja active Pending
- 2003-10-22 DE DE60334134T patent/DE60334134D1/de not_active Expired - Lifetime
- 2003-10-22 AT AT03758746T patent/ATE480240T1/de active
- 2003-10-22 EP EP03758746A patent/EP1553953B1/de not_active Expired - Lifetime
- 2003-10-22 EP EP10171708A patent/EP2253322A1/de not_active Withdrawn
- 2003-10-22 AU AU2003274734A patent/AU2003274734A1/en not_active Abandoned
- 2003-10-22 WO PCT/JP2003/013452 patent/WO2004037267A1/en not_active Ceased
-
2006
- 2006-05-23 US US11/438,290 patent/US8673973B2/en not_active Expired - Fee Related
-
2012
- 2012-05-31 JP JP2012125019A patent/JP2012162570A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US8673973B2 (en) | 2014-03-18 |
| DK1553953T3 (da) | 2010-10-25 |
| EP1553953B1 (de) | 2010-09-08 |
| EP2253322A1 (de) | 2010-11-24 |
| US20060205725A1 (en) | 2006-09-14 |
| AU2003274734A1 (en) | 2004-05-13 |
| CA2502437C (en) | 2012-07-17 |
| US7074827B2 (en) | 2006-07-11 |
| US20040082660A1 (en) | 2004-04-29 |
| JP2006503913A (ja) | 2006-02-02 |
| CA2502437A1 (en) | 2004-05-06 |
| DE60334134D1 (de) | 2010-10-21 |
| WO2004037267A1 (en) | 2004-05-06 |
| JP2012162570A (ja) | 2012-08-30 |
| EP1553953A1 (de) | 2005-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE480240T1 (de) | Zusammensetzung enthaltend latanoprost und behandlungsmethode von erhöhtem augeninnendruck und glaukom | |
| WO2006066103A3 (en) | Ophthalmic implant for treatment of glaucoma | |
| WO2006071548A3 (en) | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases | |
| BR0210241A (pt) | Piranoindazóis e seu uso no tratamento de glaucoma | |
| DE69521620D1 (de) | Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom | |
| WO2003047513A3 (en) | Method for treating ocular hypertension | |
| ES2062102T3 (es) | Derivados de prostaglandinas para el tratamiento de glaucoma o hipertension ocular. | |
| TW200733964A (en) | (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating rho kinase-mediated diseases and conditions | |
| ATE274918T1 (de) | Albumin als aktiven bestandteil zur behandlung von bindehaut- und hornhautverletzungen und von trockenen augen | |
| ATE359794T1 (de) | 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes | |
| EP1110554A4 (de) | Medizinische zusammensetzungen zur behandlung von augenerkrankungen | |
| WO2002009702A3 (en) | Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure | |
| CY1108983T1 (el) | Μιμητικα της υπεροξειδικης δισμουτασης για την αγωγη οφθαλμικων διαταραχων και νοσων | |
| ATE223200T1 (de) | Einen carboanhydrase-hemmer und xanthangummi enthaltendes augenarzneimittel | |
| BR0210238A (pt) | Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma | |
| DE60130872D1 (de) | Verfahren und mittel zur behandlung und vorbeugung von erkrankungen der hinteren augenkammer | |
| NO20052751L (no) | Oftalmisk preparat for behandling av okulaer hypertensjon. | |
| ATE453395T1 (de) | 3, 7 oder 3 und 7 thia- oder oxaprostansäure derivate als mittel zur senkung des augeninnendrucks | |
| EA200701134A1 (ru) | Средство для профилактики или лечения глаукомы | |
| WO2004043354A3 (en) | Ophthalmic compositions for treating ocular hypertension | |
| ATE216889T1 (de) | Anwendung von prostagrandin-analogen für die behandlung von glaukome und okuläre hypertension | |
| ATE404189T1 (de) | Statine zur behandlung von okularer hypertonie und glaukom | |
| DE69834638D1 (de) | Heilende zusammensetzung für intraokulare hypertension oder glaukom | |
| AU2001267864A1 (en) | Remedial agent for optic nerve disease and the like | |
| BR0316775A (pt) | Novos análogos de benzopirano e seu uso para o tratamento de glaucoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1553953 Country of ref document: EP |